title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - Climb Bio  ( NASDAQ:CLYM ) ",20241111T120000,https://www.benzinga.com/pressreleases/24/11/g41875065/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board,BMY,0.055881,Neutral,-0.043982
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board",20241111T120000,https://www.globenewswire.com/news-release/2024/11/11/2978194/0/en/Climb-Bio-Appoints-Douglas-E-Williams-Ph-D-as-Chair-of-the-Board.html,BMY,0.033468,Neutral,-0.042717
"Researchers return to Alzheimer's vaccines, buoyed by recent drug success",20231120T111500,https://www.reuters.com/business/healthcare-pharmaceuticals/researchers-return-alzheimers-vaccines-buoyed-by-recent-drug-success-2023-11-20/,BMY,0.041682,Neutral,0.0
"Stablix Appoints Douglas Williams, Ph.D., to Board of Directors",20230118T120047,https://www.benzinga.com/pressreleases/23/01/g30458105/stablix-appoints-douglas-williams-ph-d-to-board-of-directors,BMY,0.063425,Neutral,-0.038049
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win - Biogen  ( NASDAQ:BIIB ) ,20220928T201722,https://www.benzinga.com/general/biotech/22/09/29061026/these-stocks-are-on-the-radar-after-biogen-eisais-surprising-alzheimers-trial-win,BMY,0.112269,Neutral,0.0
ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer,20240122T130000,https://www.prnewswire.com/news-releases/immunobrain-checkpoint-appoints-dr-sanjay-keswani-as-chief-executive-officer-302039635.html,BMY,0.065685,Neutral,0.085332
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,BMY,0.052656,Neutral,0.017928
"Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update",20220815T110000,https://www.globenewswire.com/news-release/2022/08/15/2498065/0/en/Pyxis-Oncology-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2022-and-Provides-Pipeline-Update.html,BMY,0.024597,Neutral,-0.011764
68 Biggest Movers From Yesterday,20220419T083535,https://www.benzinga.com/news/22/04/26681653/68-biggest-movers-from-yesterday,BMY,0.02852,Neutral,0.006314
Stock Market Holds On To Gains; Nvidia Stock Lifts As Earnings Loom,20231120T160300,https://www.investors.com/market-trend/stock-market-today/stock-market-pulls-ahead-to-start-holiday-week-boeing-leads-the-dow/,BMY,0.09347,Neutral,-0.072683
"Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight",20240409T214100,https://www.prnewswire.com/news-releases/global-tissue-banking-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2030-assesses-delveinsight-302110459.html,BMY,0.045962,Neutral,0.044896
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",20240124T220100,https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,BMY,0.025985,Neutral,0.033663
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",20240115T220500,https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,BMY,0.093561,Neutral,0.092837
Compass Pathways appoints Teri Loxam as Chief Financial Officer,20231207T124337,https://investingnews.com/compass-pathways-appoints-teri-loxam-as-chief-financial-officer/,BMY,0.032513,Neutral,0.118414
Compass Pathways appoints Teri Loxam as Chief Financial Officer - Compass Pathways  ( NASDAQ:CMPS ) ,20231207T120000,https://www.benzinga.com/pressreleases/23/12/g36130382/compass-pathways-appoints-teri-loxam-as-chief-financial-officer,BMY,0.030759,Neutral,0.117589
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors,20220519T114357,https://investingnews.com/cardiol-therapeutics-appoints-teri-loxam-and-chris-waddick-to-its-board-of-directors/,BMY,0.028708,Neutral,0.024397
34 Stocks Moving In Monday's Mid-Day Session,20220418T161356,https://www.benzinga.com/news/22/04/26671086/34-stocks-moving-in-mondays-mid-day-session,BMY,0.055377,Neutral,0.001603
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,BMY,0.044386,Neutral,-0.047896
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,BMY,0.044386,Neutral,-0.047896
"Oral Transmucosal Drug Market to Hit USD 27 billion by 2031, at a CAGR 6%| Says Transparency Market Research, Inc.",20240105T113000,https://www.benzinga.com/pressreleases/24/01/g36506871/oral-transmucosal-drug-market-to-hit-usd-27-billion-by-2031-at-a-cagr-6-says-transparency-market-r,BMY,0.034136,Neutral,0.058626
"Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar",20240111T220100,https://www.prnewswire.com/news-releases/gastroenteropancreatic-neuroendocrine-tumors-market-to-showcase-a-significant-growth-by-2032-evaluates-delveinsight--key-players---eli-lilly-and-company-phanes-therapeutics-camurus-ab-advanced-accelerator-applications-pharma-302032286.html,BMY,0.025139,Neutral,0.034515
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,BMY,0.023102,Neutral,-0.093525
"Stocks That Hit 52-Week Lows On Wednesday - Bristol-Myers Squibb Company Common Stock  ( NYSE:BMY ) , SenesTech, Inc. - Common Stock  ( NASDAQ:SNES ) ",20231004T160117,https://www.benzinga.com/markets/options/23/10/35092508/stocks-that-hit-52-week-lows-on-wednesday,BMY,0.025413,Neutral,-0.094732
"Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors",20230327T120000,https://www.prnewswire.com/news-releases/aadi-bioscience-appoints-mohammad-hirmand-md-to-board-of-directors-301781997.html,BMY,0.043579,Neutral,-0.00491
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates,20230228T210100,https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-fourth-quarter-and-full-year-2022-financial-results-and-recent-corporate-updates-301758465.html,BMY,0.021484,Neutral,0.0
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,BMY,0.086948,Neutral,-0.040696
"Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results - ATN International  ( NASDAQ:ATNI ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20240425T183233,https://www.benzinga.com/news/earnings/24/04/38441305/crude-oil-moves-higher-bristol-myers-squibb-shares-fall-after-q1-results,BMY,0.180685,Neutral,-0.033345
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,BMY,0.041466,Neutral,-0.038518
Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board,20220816T123000,https://www.globenewswire.com/news-release/2022/08/16/2499067/0/en/Processa-Pharmaceuticals-Appoints-Khoso-Baluch-and-James-Neal-to-its-Board-of-Directors-and-Justin-Yorke-to-Chairman-of-the-Board.html,BMY,0.046816,Neutral,0.026632
99 Biggest Movers From Yesterday,20220512T082956,https://www.benzinga.com/news/22/05/27156577/99-biggest-movers-from-yesterday,BMY,0.021239,Neutral,0.148796
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,BMY,0.078099,Neutral,0.0
Recap Of Friday's Biotech Catalysts - End Of The Day Summary,20220722T215911,https://www.benzinga.com/general/biotech/22/07/28176253/recap-of-fridays-biotech-catalysts-end-of-the-day-summary,BMY,0.138464,Somewhat-Bullish,0.189661
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer,20230911T103000,https://www.globenewswire.com/news-release/2023/09/11/2740616/0/en/SpringWorks-Therapeutics-Appoints-Dr-Tai-An-Lin-as-Chief-Scientific-Officer.html,BMY,0.038717,Neutral,0.010654
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ,20230911T103000,https://www.benzinga.com/pressreleases/23/09/g34432690/springworks-therapeutics-appoints-dr-tai-an-lin-as-chief-scientific-officer,BMY,0.037098,Neutral,0.010592
"Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors",20230330T113000,https://www.globenewswire.com/news-release/2023/03/30/2637531/16626/en/Zevra-Therapeutics-Appoints-Biopharma-Veteran-Wendy-Dixon-Ph-D-to-Board-of-Directors.html,BMY,0.066139,Neutral,0.070237
"Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors",20220613T200100,https://www.globenewswire.com/news-release/2022/06/13/2461601/0/en/Iovance-Biotherapeutics-Appoints-Wendy-L-Dixon-Ph-D-to-Board-of-Directors.html,BMY,0.029501,Neutral,0.032284
"Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors",20220613T200100,https://www.benzinga.com/pressreleases/22/06/g27684549/iovance-biotherapeutics-appoints-wendy-l-dixon-ph-d-to-board-of-directors,BMY,0.028285,Neutral,0.032969
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,BMY,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,BMY,0.080638,Neutral,0.047754
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,BMY,0.020404,Neutral,0.078882
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",20230130T105418,https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,BMY,0.035983,Bullish,0.353198
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors,20230104T213000,https://www.globenewswire.com/news-release/2023/01/04/2583300/0/en/MacroGenics-Announces-Appointment-of-Dr-Margaret-Liu-and-Meenu-Chhabra-Karson-to-Board-of-Directors.html,BMY,0.030918,Neutral,0.08884
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors - Macrogenics  ( NASDAQ:MGNX ) ,20230104T213000,https://www.benzinga.com/pressreleases/23/01/g30283535/macrogenics-announces-appointment-of-dr-margaret-liu-and-meenu-chhabra-karson-to-board-of-director,BMY,0.030602,Neutral,0.087755
"Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development",20220822T110000,https://www.benzinga.com/pressreleases/22/08/g28581547/bright-peak-therapeutics-announces-the-appointment-of-cancer-immunotherapy-leader-jon-wigginton-m-,BMY,0.046363,Neutral,-0.032716
"Stocks That Hit 52-Week Lows On Thursday - PRA Group  ( NASDAQ:PRAA ) , Perimeter Solutions  ( NYSE:PRM ) ",20231005T172202,https://www.benzinga.com/news/23/10/35111787/stocks-that-hit-52-week-lows-on-thursday,BMY,0.013047,Neutral,0.004444
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023,20240307T210700,https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-updates-and-financial-results-for-the-fourth-quarter-and-full-year-2023-302083497.html,BMY,0.028188,Neutral,0.060752
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",20230925T210100,https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,BMY,0.130723,Neutral,0.049466
Global Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical Therapies & Recent Advances in CAR-T Cell Engineering Propelling Sector,20220811T124836,https://www.benzinga.com/pressreleases/22/08/g28454185/global-engineered-t-cells-market-report-2022-2027-increasing-demand-for-innovative-biopharmaceutic,BMY,0.039745,Neutral,0.0
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why,20220630T212500,https://www.investors.com/research/nyse-stocks-to-watch-buy/,BMY,0.110908,Neutral,-0.011156
"The Week Ahead In Biotech  ( June 5-11 ) : Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",20220605T200922,https://www.benzinga.com/general/biotech/22/06/27558552/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnin,BMY,0.121866,Neutral,0.080129
"Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday - Kohl's  ( NYSE:KSS ) ",20240828T141742,https://www.benzinga.com/news/24/08/40602596/kohls-posts-upbeat-q2-earnings-joins-box-waldencast-aerovironment-and-other-big-stocks-moving-higher,BMY,0.188193,Neutral,0.0
Anaveon appoints Dieter Weinand as Chair of its Board of Directors,20240730T060000,https://www.benzinga.com/pressreleases/24/07/g40028529/anaveon-appoints-dieter-weinand-as-chair-of-its-board-of-directors,BMY,0.090134,Neutral,0.038482
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Replimune Group  ( NASDAQ:REPL ) ,20240606T161620,https://www.benzinga.com/general/biotech/24/06/39211109/why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday,BMY,0.232439,Neutral,-0.123045
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20230603T181500,https://www.globenewswire.com/news-release/2023/06/03/2681534/0/en/Replimune-Presents-RP1-Data-from-the-IGNYTE-anti-PD1-Failed-Melanoma-Cohort-and-RP2-Data-in-Uveal-Melanoma-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,BMY,0.054857,Neutral,-0.003
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors,20221214T123000,https://www.benzinga.com/pressreleases/22/12/g30073538/umoja-biopharma-appoints-dieter-weinand-as-the-chair-of-its-board-of-directors,BMY,0.055751,Neutral,0.047895
"Why Replimune  ( REPL )  Shares Are Trading Higher Today - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",20221207T150511,https://www.benzinga.com/general/biotech/22/12/29991461/replimune-shares-surge-after-early-data-from-pretreated-melanoma-patients,BMY,0.308891,Somewhat-Bearish,-0.187502
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update - Replimune Group  ( NASDAQ:REPL ) ,20221207T120000,https://www.benzinga.com/pressreleases/22/12/g29988444/replimune-announces-positive-initial-data-from-the-anti-pd1-failed-melanoma-cohort-of-the-ignyte-c,BMY,0.03443,Neutral,-0.076535
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update,20221207T120000,https://www.globenewswire.com/news-release/2022/12/07/2569129/0/en/Replimune-Announces-Positive-Initial-Data-from-the-Anti-PD1-Failed-Melanoma-Cohort-of-the-IGNYTE-Clinical-Trial-an-RP2-3-Program-Update.html,BMY,0.033751,Neutral,-0.019351
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma,20221207T113000,https://www.globenewswire.com/news-release/2022/12/07/2569082/0/en/Replimune-Enters-into-Clinical-Collaboration-Agreement-with-Roche-for-the-Development-of-RP3-In-Colorectal-Cancer-and-Hepatocellular-Carcinoma.html,BMY,0.039289,Neutral,0.130186
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks,20220824T115800,https://www.fool.com/investing/2022/08/24/billionaires-are-scooping-up-these-2-beaten-down-b/,BMY,0.050254,Neutral,0.00702
Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220526T211500,https://www.benzinga.com/pressreleases/22/05/g27432191/replimune-to-present-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting,BMY,0.061378,Neutral,0.009621
Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting,20220526T211500,https://www.globenewswire.com/news-release/2022/05/26/2451683/0/en/Replimune-To-Present-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html,BMY,0.069164,Neutral,0.010004
"Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies",20220330T110000,https://www.benzinga.com/pressreleases/22/03/g26367562/replimune-provides-new-clinical-data-broad-program-update-and-future-development-strategy-for-its-,BMY,0.028664,Neutral,0.011514
"Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies",20220330T110000,https://www.globenewswire.com/news-release/2022/03/30/2412692/0/en/Replimune-Provides-New-Clinical-Data-Broad-Program-Update-and-Future-Development-Strategy-for-its-Tumor-Directed-Oncolytic-Immunotherapies.html,BMY,0.04356,Neutral,0.0116
"The Week Ahead In Biotech  ( March 27-April 2 ) : Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",20220327T204003,https://www.benzinga.com/general/biotech/22/03/26313832/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-fo,BMY,0.074856,Neutral,-0.002725
"Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20231108T145000,https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor,BMY,0.156461,Neutral,0.115839
